Anavex Life Sciences 관리
관리 기준 확인 4/4
Anavex Life Sciences CEO는 Chris Missling, Jul2013 에 임명되었습니다 의 임기는 11.33 년입니다. 총 연간 보상은 $ 3.89M, 18% 로 구성됩니다. 18% 급여 및 82% 보너스(회사 주식 및 옵션 포함). 는 $ 11.39M 가치에 해당하는 회사 주식의 1.47% 직접 소유합니다. 11.39M. 경영진과 이사회의 평균 재임 기간은 각각 2.8 년과 10.5 년입니다.
주요 정보
Chris Missling
최고 경영자
US$3.9m
총 보상
| CEO 급여 비율 | 18.0% |
| CEO 임기 | 11.3yrs |
| CEO 소유권 | 1.5% |
| 경영진 평균 재임 기간 | 2.8yrs |
| 이사회 평균 재임 기간 | 10.5yrs |
최근 관리 업데이트
Recent updates
Anavex, Cassava Sciences, Panax Ginseng, And The Long-Term Treatment Of Alzheimer's Disease
Nov 11Anavex: Understanding Their Latest Alzheimer's Data News With Caution
Nov 05Anavex Stock: A Risky Bet On CNS Drug Development (Rating Downgrade)
Oct 08Anavex Life Sciences: Short-Lived Spike On Latest Alzheimer's Data Not Surprising
Jul 29Companies Like Anavex Life Sciences (NASDAQ:AVXL) Are In A Position To Invest In Growth
Jul 17
Here's Why We're Not Too Worried About Anavex Life Sciences' (NASDAQ:AVXL) Cash Burn Situation
Apr 01Here's Why We're Not At All Concerned With Anavex Life Sciences' (NASDAQ:AVXL) Cash Burn Situation
Sep 19We're Interested To See How Anavex Life Sciences (NASDAQ:AVXL) Uses Its Cash Hoard To Grow
May 10Companies Like Anavex Life Sciences (NASDAQ:AVXL) Can Afford To Invest In Growth
Jan 16We Think Anavex Life Sciences (NASDAQ:AVXL) Can Easily Afford To Drive Business Growth
Oct 01Anavex Life Sciences: Upcoming Readouts In Alzheimer's And Parkinson's Disease Dementia
Sep 19Anavex's Blarcamesine And Other Disease Modifying Treatments For Alzheimer's Disease
Sep 07Anavex Life Sciences GAAP EPS of -$0.16 beats by $0.01
Aug 09We Think Anavex Life Sciences (NASDAQ:AVXL) Can Easily Afford To Drive Business Growth
Jun 17Anavex: Increasing Shareholder Value Against All Odds
May 31Anavex's Blarcamesine And Cassava Sciences' Simufilam: The Stabilization Period For Alzheimer's Disease
Mar 23We're Not Worried About Anavex Life Sciences' (NASDAQ:AVXL) Cash Burn
Mar 03Anavex 2-73: A Likely Effective Treatment For Alzheimer's Disease
Feb 09Anavex: Misunderstood Data And Possible Positive FDA Meeting Can Lead To Great Trade Opportunity
Feb 02Anavex: 2022 Has Major, Pivotal Catalysts
Jan 17Anavex Life Sciences (NASDAQ:AVXL) Is In A Strong Position To Grow Its Business
Nov 16Alzheimer's - Cassava, Cortexyme Or Anavex: Who Will Come On Top?
Nov 05Anavex Life Sciences: Still Room To Run
Aug 29Anavex Life Sciences (NASDAQ:AVXL) Is In A Strong Position To Grow Its Business
Jul 30Anavex: A Catalyst-Rich Year
Jul 05Virpax Pharmaceuticals, Anavex Life Sciences leads healthcare gainers; Aptevo Therapeutics, Intec Pharma among major losers
Jun 21Anavex Life outlines mechanism of ANAVEX2-73 and ANAVEX3-71 in treatment of Alzheimer's Disease
Jun 14Anavex Life's late-stage ANAVEX2-73 study in Alzheimer’s exceeds target enrollment
Jun 08Anavex, Cyclo Therapeutics, And Green Valley: Stalling The Progression Of Alzheimer's Disease
Apr 28Anavex Life Sciences (NASDAQ:AVXL) Is In A Strong Position To Grow Its Business
Apr 16CEO 보상 분석
| 날짜 | 총 보상 | 급여 | 회사 수익 |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$42m |
| Mar 31 2024 | n/a | n/a | -US$41m |
| Dec 31 2023 | n/a | n/a | -US$43m |
| Sep 30 2023 | US$4m | US$700k | -US$48m |
| Jun 30 2023 | n/a | n/a | -US$52m |
| Mar 31 2023 | n/a | n/a | -US$53m |
| Dec 31 2022 | n/a | n/a | -US$50m |
| Sep 30 2022 | US$7m | US$586k | -US$48m |
| Jun 30 2022 | n/a | n/a | -US$45m |
| Mar 31 2022 | n/a | n/a | -US$43m |
| Dec 31 2021 | n/a | n/a | -US$41m |
| Sep 30 2021 | US$9m | US$550k | -US$38m |
| Jun 30 2021 | n/a | n/a | -US$32m |
| Mar 31 2021 | n/a | n/a | -US$28m |
| Dec 31 2020 | n/a | n/a | -US$28m |
| Sep 30 2020 | US$2m | US$550k | -US$26m |
| Jun 30 2020 | n/a | n/a | -US$26m |
| Mar 31 2020 | n/a | n/a | -US$26m |
| Dec 31 2019 | n/a | n/a | -US$26m |
| Sep 30 2019 | US$3m | US$513k | -US$26m |
| Jun 30 2019 | n/a | n/a | -US$26m |
| Mar 31 2019 | n/a | n/a | -US$23m |
| Dec 31 2018 | n/a | n/a | -US$20m |
| Sep 30 2018 | US$3m | US$500k | -US$17m |
보상 대 시장: Chris 의 총 보상 ($USD 3.89M )은 US 시장에서 비슷한 규모의 회사의 평균 수준입니다( $USD 3.17M ).
보상과 수익: Chris 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.
CEO
Chris Missling (58 yo)
11.3yrs
테뉴어
US$3,894,453
보상
Dr. Christopher U. Missling, also known as the Chris, MS, Ph D., MBA, has been the Chief Executive Officer and President at Anavex Life Sciences Corp. since July 05, 2013 and also serves as its Director an...
리더십 팀
| 이름 | 위치 | 테뉴어 | 보상 | 소유권 |
|---|---|---|---|---|
| President | 11.3yrs | US$3.89m | 1.47% $ 11.4m | |
| Principal Financial Officer & Treasurer | 9.1yrs | US$501.06k | 0.027% $ 209.2k | |
| Chief Scientific Officer | 2.8yrs | 데이터 없음 | 데이터 없음 | |
| VP of Corporate | no data | 데이터 없음 | 데이터 없음 | |
| Senior Vice President of Nonclinical Development | 3.5yrs | 데이터 없음 | 데이터 없음 | |
| Chief Medical Officer | 2.8yrs | 데이터 없음 | 데이터 없음 | |
| Head of Biostatistics | 1.7yrs | 데이터 없음 | 데이터 없음 | |
| Senior Vice President of Regulatory Affairs | less than a year | 데이터 없음 | 데이터 없음 | |
| Senior Vice President of Clinical Development | less than a year | 데이터 없음 | 데이터 없음 | |
| Senior VP & Head of Research and Development | less than a year | 데이터 없음 | 데이터 없음 |
2.8yrs
평균 재임 기간
경험이 풍부한 관리: AVXL 의 관리팀은 경험 ( 2.8 년 평균 재직 기간)으로 간주됩니다.
이사회 구성원
| 이름 | 위치 | 테뉴어 | 보상 | 소유권 |
|---|---|---|---|---|
| President | 11.3yrs | US$3.89m | 1.47% $ 11.4m | |
| Independent Chairman | 3.5yrs | US$349.54k | 데이터 없음 | |
| Member of the Scientific Advisory Board | 9.7yrs | 데이터 없음 | 데이터 없음 | |
| Member of the Scientific Advisory Board | 13.8yrs | 데이터 없음 | 데이터 없음 | |
| Member of the Scientific Advisory Board | 10.9yrs | 데이터 없음 | 데이터 없음 | |
| Member of the Scientific Advisory Board | 11yrs | 데이터 없음 | 데이터 없음 | |
| Member of the Scientific Advisory Board | no data | 데이터 없음 | 데이터 없음 | |
| Independent Director | 11.8yrs | US$341.54k | 1.54% $ 11.9m | |
| Member of the Scientific Advisory Board | 10.5yrs | 데이터 없음 | 데이터 없음 | |
| Member of the Scientific Advisory Board | 9.7yrs | 데이터 없음 | 데이터 없음 | |
| Independent Director | 9.4yrs | US$341.54k | 0.0059% $ 45.6k | |
| Lead Independent Director | 6.7yrs | US$357.54k | 데이터 없음 |
10.5yrs
평균 재임 기간
58yo
평균 연령
경험이 풍부한 이사회: AVXL 의 이사회는 노련하고 경험이 있습니다(평균 재직 기간 10.5 년).